On page 2152, in the second paragraph under “Discussion,” the investigators “observed better survival in gilteritinib-arm DNMT3A/NPM1 comutated patients,” not “c-mutated patients.”
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2022
